Newcastle Clinical Trials Unit

Spirit 2

Spirit 2

STI571 Prospective International RandomIsed Trial 2 – A phase III, prospective randomised comparison of imatinib 400mg daily versus dasatinib 100mg in patients with newly-diagnosed chronic phase chronic myeloid leukaemia.

  • Study stage: Closed
  • Sponsor:  The Newcastle Upon Tyne Hospitals NHS Foundation Trust
  • Funder:  IIT (Bristol Myer Sqibb)
  • Therapeutic area: Cancer and Neoplasm
  • Type of study:  CTIMP

Aim: To compare 5 year event free survival between the treatment arms.

  • Clinical Phase: III
  • Population: Adult
  • Design: RCT
  • Setting: Secondary Care
  • Planned Sample Size: 810